Voriconazole (ZP-059)
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04229303 NCT04229303 · Allergic Bronchopulmonary Aspergillosis This trial was open-label with no blinding and no placebo control, splitting a modest number of participants into several small dosing cohorts of 6 to 8 people whose only formal endpoint was the adverse-event rate; there was no controlled comparison capable of showing an effect on the underlying disease. Registry: NCT04229303 | 1 | Number of Participants With Treatment-Emergent Adverse Events (TEAE) (Part 1: screening (Day -28 to -1) to follow-up (8 to 12 days after last dose); part 2: screening (Day -28 to -1) to follow-up (11-17 days after last dose); Part 3: screening (Day -28 to -1) to follow-up (8-12 days after last dose of study drug).) 2020-08-31 | Number of Participants With Treatment-Emergent Adverse Events (TEAE) (Part 1: screening (Day -28 to -1) to follow-up (8 to 12 days after last dose); part 2: screening (Day -28 to -1) to follow-up (11-17 days after last dose); Part 3: screening (Day -28 to -1) to follow-up (8-12 days after last dose of study drug).): Part 1 - ZP-059 5mg — Total number of subjects with at least 1 TEAE: 0 participants; Total number of subjects with at least 1 serious TEAE: 0 participants; Total number of subjects with at least 1 mild TEAE: 0 participants; Total number of subjects with at least 1 moderate TEAE: 0 participants; Total number of subjects with at least 1 severe TEAE: 0 participants; Total number of subjects with at least 1 treatment-related TEAE: 0 participants; Total number of subjects with at least 1 non treatment-related TEAE: 0 participants | Part 1 - ZP-059 10mg — Total number of subjects with at least 1 TEAE: 3 participants; Total number of subjects with at least 1 serious TEAE: 0 participants; Total number of subjects with at least 1 mild TEAE: 2 participants; Total number of subjects with at least 1 moderate TEAE: 1 participants; Total number of subjects with at least 1 severe TEAE: 0 participants; Total number of subjects with at least 1 treatment-related TEAE: 0 participants; Total number of subjects with at least 1 non treatment-related TEAE: 3 participants | Part 1 - ZP-059 20mg — Total number of subjects with at least 1 TEAE: 2 participants; Total number of subjects with at least 1 serious TEAE: 0 participants; Total number of subjects with at least 1 mild TEAE: 2 participants; Total number of subjects with at least 1 moderate TEAE: 0 participants; Total number of subjects with at least 1 severe TEAE: 0 participants; Total number of subjects with at least 1 treatment-related TEAE: 0 participants; Total number of subjects with at least 1 non treatment-related TEAE: 2 participants | Part 1 - ZP-059 40mg — Total number of subjects with at least 1 TEAE: 2 participants; Total number of subjects with at least 1 serious TEAE: 0 participants; Total number of subjects with at least 1 mild TEAE: 1 participants; Total number of subjects with at least 1 moderate TEAE: 1 participants; Total number of subjects with at least 1 severe TEAE: 0 participants; Total number of subjects with at least 1 treatment-related TEAE: 0 participants; Total number of subjects with at least 1 non treatment-related TEAE: 2 participants | Part 2 - ZP-059 10mg Bid — Total number of subjects with at least 1 TEAE: 5 participants; Total number of subjects with at least 1 serious TEAE: 0 participants; Total number of subjects with at least 1 mild TEAE: 3 participants; Total number of subjects with at least 1 moderate TEAE: 2 participants; Total number of subjects with at least 1 severe TEAE: 0 participants; Total number of subjects with at least 1 treatment-related TEAE: 4 participants; Total number of subjects with at least 1 non treatment-related TEAE: 1 participants | Part 2 - ZP-059 20mg Bid — Total number of subjects with at least 1 TEAE: 4 participants; Total number of subjects with at least 1 serious TEAE: 0 participants; Total number of subjects with at least 1 mild TEAE: 3 participants; Total number of subjects with at least 1 moderate TEAE: 1 participants; Total number of subjects with at least 1 severe TEAE: 0 participants; Total number of subjects with at least 1 treatment-related TEAE: 0 participants; Total number of subjects with at least 1 non treatment-related TEAE: 4 participants | Part 2 - ZP-059 40mg qd — Total number of subjects with at least 1 TEAE: 4 participants; Total number of subjects with at least 1 serious TEAE: 0 participants; Total number of subjects with at least 1 mild TEAE: 2 participants; Total number of subjects with at least 1 moderate TEAE: 2 participants; Total number of subjects with at least 1 severe TEAE: 0 participants; Total number of subjects with at least 1 treatment-related TEAE: 1 participants; Total number of subjects with at least 1 non treatment-related TEAE: 3 participants | Part 3 - ZP-059 20mg — Total number of subjects with at least 1 TEAE: 9 participants; Total number of subjects with at least 1 serious TEAE: 0 participants; Total number of subjects with at least 1 mild TEAE: 8 participants; Total number of subjects with at least 1 moderate TEAE: 1 participants; Total number of subjects with at least 1 severe TEAE: 0 participants; Total number of subjects with at least 1 treatment-related TEAE: 7 participants; Total number of subjects with at least 1 non treatment-related TEAE: 2 participants | Part 3 - Oral Voriconazole 200mg — Total number of subjects with at least 1 TEAE: 7 participants; Total number of subjects with at least 1 serious TEAE: 0 participants; Total number of subjects with at least 1 mild TEAE: 5 participants; Total number of subjects with at least 1 moderate TEAE: 2 participants; Total number of subjects with at least 1 severe TEAE: 0 participants; Total number of subjects with at least 1 treatment-related TEAE: 0 participants; Total number of subjects with at least 1 non treatment-related TEAE: 7 participants | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Allergic Bronchopulmonary Aspergillosis: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Voriconazole (ZP-059): this drug | Phase 1 | Small molecule | fungal CYP51 / lanosterol 14-alpha-demethylase | Weak signal | Featured results are safety only in this race | |
| Itraconazole (PUR1900) | Phase 2 | Small molecule | fungal CYP51 (lanosterol 14α-demethylase) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.